| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | 1 | N | 1 Adjuvant Arm | 342 | 173 | 49 | 21 | 8 | 0 | 0 | 02/15/2019 | 312 | 122 |
| 2 Neoadjuvant Pembrolizumab | 172 | 46 | 22 | 8 | 0 | 0 | ||||||||
| 345 | 95 | 43 | 16 | 0 | 0 | |||||||||
| 2 | Y | 3 Surgery | 314 | 94 | 45 | 24 | 5 | 2 | 02/15/2019 | |||||
| 314 | 94 | 45 | 24 | 5 | 2 | |||||||||
| 3 | Y | 4 Post-Surgery Pembro | 261 | 86 | 41 | 21 | 9 | 0 | 02/15/2019 | |||||
| 261 | 86 | 41 | 21 | 9 | 0 | |||||||||
| S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | 1 | Y | 1 Encorafenib/Binimetinib/Nivolu | 112 | 5 | 3 | 0 | 0 | 0 | 0 | 01/06/2021 | 108 | 50 | |
| 2 Ipilimumab + Nivolumab | 7 | 4 | 2 | 2 | 1 | 0 | ||||||||
| 12 | 7 | 2 | 2 | 1 | 0 | |||||||||
| Yes | EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim | 1 | E | Total Registrations | 46 | 7 | 4 | 3 | 0 | 0 | 03/25/2016 | 187 | 82 | |
| 46 | 7 | 4 | 3 | 0 | 0 | |||||||||
| No | EA6174-Merkel, Adjuvant Pembrolizumab vs Observation | 1 | E | Total Registrations | 42 | 16 | 6 | 2 | 0 | 0 | 05/01/2019 | 279 | 109 | |
| 42 | 16 | 6 | 2 | 0 | 0 | |||||||||
| EA6192-Melan, Adv, Erly Discont of Antibdy Thrpy | 0 | E | Total Registrations | 2 | 2 | 1 | 0 | 0 | 0 | 09/22/2021 | 136 | 45 | ||
| 2 | 2 | 1 | 0 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 3 | 3 | 1 | 0 | 0 | 0 | 09/22/2021 | |||||
| 3 | 3 | 1 | 0 | 0 | 0 | |||||||||